selective toxicity
Selective toxicity is the founding principle of anti-infective drugs: hurt the pathogen badly while barely touching the human host. It is the difference between a poison and a medicine — a true antibiotic is a poison aimed so precisely that it ruins the germ but spares you.
The trick is exploiting biochemical differences between microbe and host. The cleanest case is a target the pathogen has and we do not: bacteria build a peptidoglycan cell wall and make their own folate, so drugs hitting those steps are lethal to bacteria and inert in us. When the target is shared but subtly different — like bacterial versus human ribosomes — the drug must bind the microbial version far more tightly to stay selective.
Selective toxicity is hardest where the pathogen most resembles us. Viruses hijack our own cellular machinery, fungi are eukaryotes like us, and parasites are complex animals, so antivirals, antifungals, and antiparasitics are far harder to make non-toxic than antibacterials. The honest measure of how well a drug achieves selectivity in the body is its therapeutic index — the gap between an effective dose and a harmful one.
Beta-lactams achieve near-perfect selective toxicity because their target, the cell-wall-cross-linking enzyme, simply does not exist in human cells.
A target absent in humans is the ideal recipe for safety.
The concept is often credited to Paul Ehrlich's idea of a magic bullet — a drug that travels to and harms only the disease-causing target.